|
The Editors |
Dan Stradford, Editor
Alan Graham, Assistant Editor
Gloria McTaggart, Assistant Editor
SafeHarborProj@aol.com
www.AlternativeMentalHealth.com
Feedback: We'd like to hear your
comments and views. Please forward them to the e-mail address above.
Contact information is below.
|
|
Subscriptions |
Did someone forward this
ezine to you? You can subscribe for yourself by visiting our web site
and using the sign-up form there, or just by sending a blank e-mail
to...
amh.10@add.mb00.net
Complete unsubscribing instructions are at the end of this message.
Or, you can reply to this message and ask to be removed from the list.
|
|
About Safe Harbor |
|
Safe Harbor was founded in
1998 in the wake of growing public dissatisfaction with the unwanted
effects of orthodox psychiatric treatments such as medication and shock
therapy. Seeking to satisfy the desire for safer, more effective
treatments, Safe Harbor is dedicated to educating the public, the
medical profession, and government officials on research and treatments
that, minimally, do no harm and, optimally, cure the causes of severe
mental symptoms. Our primary thrust is education on the medical causes
of severe mental symptoms and the use of nutritional and other natural
treatments.
|
|
About AlternativeMentalHealth.com |
|
ALTERNATIVEMENTALHEALTH.COM IS THE WORLD'S LARGEST WEB SITE DEVOTED
exclusively to alternative mental health treatments. It includes a
directory of over 240 physicians, nutritionists, experts, organizations,
and facilities around the U.S. that offer or promote safe, alternative
treatments for severe mental symptoms. Many of the physicians listed do
in-depth examinations to find the physical causes behind mental
problems.
Also included on the site is an array of articles on topics ranging
from the medical causes of schizophrenia to the effects of toxic metals
on mental health.
Special AlternativeMentalHealth.com T-shirts and bumper stickers are
available at our online store.
A bookstore page lists top books that cover many areas of alternative
treatments with titles like Natural Healing for Schizophrenia and Other
Common Mental Disorders and No More Ritalin.
AlternativeMentalHealth.com has been created to educate the public,
practitioners, and government officials on the medical conditions that
create "mental illness" and the many safe resources available for
addressing and often curing severe mental symptoms.
|
| WE
WELCOME YOUR DONATIONS. AS A NONPROFIT ORGANIZATION, SAFE HARBOR IS
SUPPORTED SOLELY THROUGH THE GENEROSITY OF THE PUBLIC. DONATIONS CAN
BE MADE ONLINE AT OUR WEB SITE OR MAILED TO THE ABOVE ADDRESS. WE ALSO
ACCEPT VISA/MASTERCARD BY PHONE. THANK YOU. |
|
|
Editor's Comment |
| We at Safe Harbor want to thank all
those who attended our conference in Los Angeles, June 15-16, 2002,
entitled "Non-Pharmaceutical Approaches to Mental Disorders." Attendees
came from across the U.S. and as far away as India. It was a great
pleasure to meet many with whom we had corresponded by phone and email.
It was equally satisfying to hear from so many of those in attendance
who said they would take the data learned back to their respective
corners of the world and make good use of it.
"What a fantastic conference," one healthcare professional wrote us.
"You have no idea how much it energized me to do what I need to do back
in New England. I know a lot of people are going to be helped now in my
area who have had no hope before."
Thank YOU. Why do our staff and volunteers work long hours, usually
for no pay? It's so that some day the information in this ezine and on
our website will be known and in use in mental health facilities around
the world. It's so that doctors and psychiatrists can some day be a
Safe Harbor themselves where patients don't dread to go for fear of
being drugged into oblivion or worse. It's so that some day the word
"recovered" will mean actually getting well and not "getting your meds
fine-tuned."
Thanks for coming and doing your part.
|
|
Announcement: Safe Harbor
Conference Tapes Available |
| Safe Harbor is pleased to announce
that tapes are now available of our conference held in Los Angeles
on June 15 and 16: "Non-Pharmaceutical Approaches to Mental
Disorders." For most of the tapes, lecture notes and copies the
accompanying Powerpoint slides are included.
To purchase tapes, go to
http://www.alternativementalhealth.com/orderconf.htm |
Lecture titles include:
 | Introduction to Conference by Dan Stradford, President of Safe
Harbor |
 | Basic Brain Science and Brain Metabolism by Prof. James Croxton
|
 | Mechanisms That Can Lead to Severe Mental Symptoms by Prof. James
Croxton |
 | Lab testing for causes of mental symptoms: Addressing the
molecular basis of chronic metabolic disorders (Lecture 1) by Jeff
Baker, ND, of Great Smokies Labs |
 | Specific Syndromes by Prof. James Croxton |
 | Lab Testing for Causes of Mental Symptoms: Addressing the
molecular basis of chronic metabolic disorders (Lecture 2) by Jeff
Baker, ND,of Great Smokies Labs |
 | Case histories, Q and A by Prof. James Croxton |
 | Natural Treatments for Addiction by Charles Gant, MD, PhD |
 | Medical Conditions that Present with Psychiatric Symptoms by
Stuart Shipko, MD:
(Note: 89% of the audience surveyed gave the content of this lecture
the highest rating possible.) |
 | Nutritional and Herbal Treatments for Anxiety and Depression by
Hyla Cass, MD |
 | The Role of Hormones in Mood Disturbance by Cynthia Watson, MD
|
 | Complementary Medicine Solutions for Children Diagnosed with
Attention Deficit Disorder by Charles Gant, MD, PhD |
 | Recovery Panel: Six individuals discuss their recoveries from
mental symptoms without drugs |
|
|
Announcement: Pfeiffer Center to
Offer Treatment in Santa Clarita, CA |
| As part of their national outreach
program, THE PFEIFFER TREATMENT CENTER will be providing patient
services in Santa Clarita, California, USA, at Residence Inn, 25320 The
Old Road, Stevenson Ranch. Dates: August 5, 6, & 7. PFEIFFER is an
outpatient clinic dedicated to assisting children and adults with
nutritional treatment of biochemical imbalances. "We offer natural,
individualized treatment emphasizing ADD, ADHD, learning disabilities,
autism, depression, thought & mood disorders. Our doctors prescribe
individualized nutrient therapy for each patient's unique biochemistry."
For information or an appointment call 630-505-0300 8:30 A.M. - 5:00
P.M. (CST) Mon.-Fri.
If you know of a family member, friend, or organization that would be
interested, please pass along this information. Promotional flyers are
available from the Center, or visit their Website at
http://www.hriptc.org.
|
|
St. John's Wort Study
Misleads Public? |
| Editor's note: The following
article was written by psychiatrist Hyla Cass, author of many books,
including two on St. John's Wort and the recently published "Natural
Highs." The study discussed by Dr. Cass in this article was
mentioned in our last issue and we are presenting Dr. Cass's article
to give a full perspective on that study. More information is
available at
http://www.cassmd.com. |
A recent study on the popular herbal
remedy St. John's wort published in the April 10 edition of the Journal
of the American Medical Association (JAMA) concluded that St. John's
wort was ineffective in treating severe forms of depression. So was the
widely prescribed antidepressant Zoloft(r) (sertraline)! The emphasis,
though, both in the article and even more so, in the media's response,
has been on the failure of St. John's wort in the treatment of
depression, ignoring many published studies that have shown conclusively
that St. John's wort is effective in the treatment of mild to moderate
depression.
Why all the fanfare over the fact that
St. John's wort is shown to be ineffective for a condition that it was
never purported to treat? The bigger news is that this study showed that
a drug with sales of over $2 billion and prescribed to millions of
Americans for severe forms of depression may be no more effective than
placebo. We are addressing a significant problem here: In the U.S,
approximately 10% of people suffer from major depression at any one
time, and 20-25% suffer a major depressive episode at some point during
their lifetime.
Speaking as a clinician who regularly
prescribes St. John's wort, I have seen repercussions from similarly
slanted interpretations of an herbal study. While the placebo effect
generally works in our favor, there can be a negative placebo effect, as
follows. After hearing this news about St John's wort, many individuals
who have been successful in relieving their depression with the herb may
question their positive response, lose confidence in it, discontinue
use, and revert to their depressive state. Many others may dismiss the
St John's wort as useless without even giving it a try. Both groups may
then turn to prescription medications, with their more severe side
effects, such as loss of libido, memory impairment, headaches, nausea,
and significant withdrawal problems. St John's wort's side effects, in
contrast, are generally mild and transitory, with no withdrawal symptoms
when it is discontinued.
St John's wort is known to have
interactions with certain drugs, almost all of these for relatively
small, specific populations (e.g. HIV patients on protease inhibitors,
transplant patients on cyclosporin, those on coumadin, etc). Despite
this, the overall risk/benefit ratio is far better than that of the
prescription medications, and the drug/herb interactions are easily
dealt with as with any active medication - with proper warnings and
patient selection. I might add that grapefruit juice has a similar
effect on drug potency, blocking liver enzymes that break down the
drugs.
Depression can be a debilitating
illness, and yet we are in effect "hexing" the use of a perfectly good
herbal medicine that has been prescribed successfully in Europe for
years as a first line treatment for mild to moderate depression. If it
doesn't work, then the patient can always be given the more powerful,
pharmaceutical antidepressants. Does St. John's wort lose its efficacy
when it crosses the Atlantic? The medical profession is bound by the
Hippocratic oath to "first do no harm," and to use the simplest, most
natural, least harmful medicines first. Why put so many people as risk?
Perhaps the most interesting finding of
this study is the power of the placebo effect, a belief in a substance's
efficacy, reflected in the improvement of the group that received the
dummy pills. In this study, the placebo group actually responded better
than both of the others (32% for placebo vs 24% for St John's wort and
Zoloft). The human mind is complex, and many factors go into the healing
process. Research shows the placebo effect to be a very significant
aspect of treatment response for almost all medications. As physicians,
we do best when we fully encourage and support it. Of course, there is
no way to tell in any one individual how much relief is due to the
placebo and how much, to the active medication, be it herb or drug. To
JAMA's credit, an accompanying editorial actually addresses the issue,
concluding that "this may be Nature's way of providing clues to
fundamental aspects of the healing process, even as advances in medicine
and the discovery of new therapies takes place. It is important to learn
from rather than dismiss the variability of the therapeutic response."
This might be the true news of this article.
We can make some generalizations about
the media, herbs, and pharmaceuticals to be considered in evaluating
this and other news stories:
The researchers' job is to get their
research published.
The journal's job is to inform, but
unfortunately, often with a pro-pharmaceutical bias. The pharmaceutical
industry is by far the largest funding source of the journals (and of
almost all of the research), as well as being one of the largest
lobbying groups in Washington. Even though this study was NIH-funded,
there is a complex web of relationships here. Most researchers also
conduct other studies that are funded by this industry.
The media's job is to sell news, and
generally, by being as sensational as possible. The public must read
between the lines to ferret out the truth, and make up their own minds.
We hope that this has been of some help in the process.
| Re: Davidson JRT et al. Effect of
Hypericum perforatum (St John's Wort) in major depressive disorder:
A randomized controlled trial. JAMA. 2002;287:1807-1814. |
|
|
Therapy Aims at Improving
Stunted Mental Functioning |
| One of the common phenomena of people
diagnosed with schizophrenia is that they often reach a point where
mental development seems to cease. Certain thinking processes and
problem-solving abilities stagnate. Since most people in this condition
are on medication, it can be impossible to sort out whether this stunted
mental growth is due to the drugs or is naturally-occurring.
This slowed development can limit the
ability of the person to gain employment, find housing, maintain a
romantic relationship, and solve a myriad of the large and small
problems of living.
The Planned Lifetime Assistance Network
(PLAN) of Northeast Ohio, a nonprofit organization, has developed a
mental exercise program that improves cognitive functions of such
patients diagnosed with schizophrenia.
Cognitive Enhancement Therapy (CET), as
it is called, is the reverse of traditional psychotherapy. Instead of
giving solutions to the patient, it gives the patient problems to
solve. Instead of interpreting the patient's remarks, it requires that
the patient explain himself. Instead of concentrating on the patient's
behavior, the focus is on his development. The accent is on ability.
In group meetings led by a "coach" (not
a therapist), the patients are given problems to solve which actually
increase their stress in a controlled environment during the session,
thus increasing their ability to tolerate stress, rather than teaching
them to always avoid stress.
Computerized puzzles are used as well as
other problem-solving methods, including improvement of social skills.
Although the organization specifically states that CET is not intended
to replace medication, PLAN reports increased and improved recovery and
increases in mature behavior, the ability to think abstractly, and the
ability to get the "gist" of a concept.
For more information, contact PLAN at
(216) 321-3611.
|
|
Recommendations May Lead to
Over-Prescription of Antidepressants |
| In recent years, the diagnosis of
depression has become more and more common.
A 1996 study done by the U.S. Preventive Services Task Force to
determine the need for routine screen of depression found "insufficient
evidence to recommend for or against the routine use of standardized
questionnaires to screen for depression in asymptomatic primary care
patients... Clinicians should, however, maintain an especially high
index of suspicion for depressive symptoms in adolescents and young
adults, persons with a family or personal history of depression, those
with chronic illnesses, those who perceive or have experienced a recent
loss, and those with sleep disorders, chronic pain, or multiple
unexplained somatic complaints."
However, In a press release of May 20, 2002, The U.S. Preventive
Services Task Force announced that the panel has reversed it's decision,
and now recommends that general practitioners screen their patients for
depression.
However, instead of screening patients who have "a family or personal
history of depression, ... chronic illnesses, ... recent loss, ... sleep
disorders, ... chronic pain, or multiple unexplained somatic
complaints," Task Force Chairman, Dr. Alfred Berg, Chair of the
Department of Family Medicine, University of Washington, Seattle, said
that the panel now recommends the use of just two simple questions:
"Over the past 2 weeks, have you ever felt down, depressed, or hopeless,
and have you felt little interest or pleasure in doing things?" He
further states that these two questions "May be as effective as using
longer screening instruments."
If the patient's answers are in the affirmative, further diagnostic
tools may be used. If the problems have lasted throughout the previous
two weeks, and have interfered with the patient's ability to perform
day-to-day tasks, doctors may make a diagnosis of depression.
Award-winning investigative reporter Nick Regush, who also served as
a consultant to the Center for Bioethics, University of Montreal,
commented on the Task Force's recommendations in a recent Redflags
Weekly (http://redflagsweekly.com)
article: "The over-prescription of anti-depressants is already
epidemic..." this type of screening "will likely lead to mindless drug
prescriptions for people who are having some common, momentary
difficulties in their lives."
Mr. Regush goes on to say, "Only a cultural/social idiot, totally
oblivious to the themes of our times, not to mention the overhanging,
ever-present threat of terrorism and a world going to hell, would ask
these types of questions as some sort of a screener for depression."
|
|
Light Therapy Useful for
Depression During Pregnancy |
| Bright-light therapy may be an
effective treatment for depression in pregnant women. The availability
of an easy-to-use, potentially non-toxic antidepressant -- light therapy
-- in pregnancy is a clinically attractive option.
Researchers conducted a pilot experiment to see whether exposure to
bright light, a technique used to treat those suffering from seasonal
affective disorder (SAD) or winter depression, might also work on women
suffering from depression during pregnancy.
Around 5% of pregnant women meet the criteria for major depression.
Doctors are justifiably reluctant to prescribe antidepressant
medications to pregnant women for fear of their effect on the fetus.
Previous research has suggested that bright light exposure may help
people suffering from major depression or from postpartum depression.
The exact mechanism has not been fully isolated. Some data suggest that
light therapy advances the timing of the daily biological clock, which
may then bring about the antidepressant effect.
Sixteen pregnant women suffering from major depression completed the
pilot study. They were instructed to expose themselves to an hour a day
of bright ultraviolet light from a light box within 10 minutes of waking
up for three to five weeks.
The patients showed a moderate improvement of their levels of
depression after just three weeks of light treatment. For the seven
women who underwent five weeks of light therapy, their average score on
a scale that measures depression improved by 59%. When the light therapy
was discontinued, the women showed signs of an increase in their levels
of depression.
| (American Journal of Psychiatry
April 2002;159:666-669) |
|
|
German Environmental Office
Issues Drug Pollution Warning |
| Earlier this year, we mentioned a UK
Sunday-Times article alerting readers that prescription drugs, including
antidepressants, were being detected in European lakes and rivers at
levels potentially destructive to aquatic life (Alternative
Mental Health News #19, "PRESCRIPTION DRUG POLLUTION THREATENS FISH,
HUMANS").
The German Federal Office for Environmental Protection issued a
warning in February that medicine manufacturers must examine
environmental risks more strictly in light of findings that even tap
water was significantly affected.
After ingestion, hormones and other stable chemical substances, as
well as their metabolites, pass into sewage and ultimately into
groundwater and even drinking water. Experts estimated that German
surface waters contain 2 micrograms per liter of the estrogen
17alpha-Ethinylestradiol from birth control pills, four times the
concentration necessary to alter breeding patterns in fish resulting in
fewer offspring.
In the year 2000, according to the agency's statistics, 29,000 tons
of medicine were sold for human consumption in Germany including 7,000
tons of synthetic chemicals. An additional 2,320 tons of animal
medications were sold in Germany that year.
While the drugs themselves have been tested on their intended users,
the effects of drug metabolites - substances produced by the body after
ingestion - are largely unknown, the agency warned.
Examining the effect of medicines on the environment is a relatively
new function of the German Federal Office for Environmental Protection.
|
|
Psychiatrists Voice
Concerns Over Drug Marketing Tactics |
| "Of course, it's going to bias us --
the question is whether the bias is benign," said David McDowell, a
Columbia University psychiatrist who helped monitor industry
sponsorships for the recent annual APA meeting in Philadelphia,
referring to the aggressive marketing of psychiatric drugs at the
convention.
Without industry money at the gigantic Philadelphia Convention
Center, added McDowell, "we'd be sitting in the basement of the YMCA."
"Let's face it -- they make the money back" through greater sales and
prescriptions, said Robert Eilers, a psychiatrist in the state Office of
Mental Health in New Jersey, in a session where several doctors assailed
top APA officials. "It's totally out of control."
The quotes appeared in Shankar Vedantam's recent expose of
pharmaceutical marketing practices at the convention. Vedantam is a
science reporter on the national desk of The Washington Post.
In the days leading up to the meeting, pharmaceutical companies
mailed attendees hundreds of free phone cards, as well as invitations to
museums, jazz concerts and fancy dinners.
The 19,000 psychiatrists arriving for the meeting were greeted by a
highway billboard advertising AstraZeneca's anti-psychotic, Seroquel.
Outside the giant convention center, curb signs for buses ferrying
doctors to their hotels advertised Prozac's manufacturer, Eli Lilly and
Co. Each attendee was handed a gray bag with the insignia of the meeting
and the orange logo of GlaxoSmithKline, maker of Paxil.
Boston Globe staff writer Ellen Barry described the contents of one
Mexican psychiatrist's goody bag:
"As a reward for attending the American Psychiatric Association's
annual meeting, she had received a small egg-shaped clock from the
makers of the antidepressant Prozac; a sleek thermos from Paxil, also an
antidepressant; and an engraved silver business card holder courtesy of
Depakote, an anticonvulsant. She got a neat little CD carrying case from
Risperdol, an antipsychotic; a passport holder from Celexa, an
antipsychotic; a neat green paperweight from Remeron, an antidepressant;
and a letter opener, representing what drug she could not remember.
"For the duration of the weekend, though, Velazquez's loyalty
belonged to Pfizer, which had paid her airfare from Mexico City (along
with 30 of her colleagues and her 18-year-old nephew) and put them all
up in hotels near the APA meeting. That night, also courtesy of Pfizer,
she would attend a glittering banquet at the Philadelphia Academy of
Fine Arts."
Concern over psychiatry's ties with industry was widespread enough to
be the focus of several panels at this year's convention. Some
psychiatrists said the association should simply sever all ties with
industry. Harvard Medical School psychiatrist David Osser suggested that
companies pool symposium money into a common fund, which could then be
used to conduct sessions chosen exclusively by mental health
professionals. Andrew Ho, a UCLA psychiatrist, said the extent of
industry involvement -- and the dependence of the association on the
money -- raised questions about who was controlling the association and
the profession.
Levine told APA officials that even patient organizations such the
National Alliance for the Mentally Ill had been shunted to the "far, far
corner of the auditorium" as funding companies got center stage in the
exhibitors' hall. "It hurts me the APA this year has become part of that
effort," he said.
"There are strings attached," agreed Stephen Goldfinger, APA's top
monitor of industry sponsorship at the conference, at a session
discussing potential conflicts of interest. "When you dance with the
devil, you can't control all the steps."
The industry-sponsored symposiums at this conference are unusual -
most major medical associations do not allow them -- said James
Thompson, APA's deputy medical director. If companies want to take
advantage of the conferences of those other groups, they have to set up
their own, independent "satellite symposiums."
Part of the APA's dependence on industry sponsorship is because the
association has been ailing financially, and revenue from the annual
convention represents about 22 percent of all funding. That money is
becoming increasingly important, as revenue from dues has dropped in
recent years from $11 million in 1998 to $9.9 million last year, and is
expected to drop further in the years ahead. The association has run at
a loss for three out of the past four years.
|
|
Book Review: Mad in
America |
| Robert Whitaker's "Mad in America" is a
must read for anyone interested in the field of mental health. The
former Boston Globe medical journalist takes a painstaking look at the
history of the treatment of America's most debilitated mental patients -
those labeled with schizophrenia and how this treatment has evolved over
the years.
What he reveals is often disturbing and sometimes shocking. He
removes the veneer of the entire mental health establishment,
challenging the notion that today's madman is better off than those of
yesteryear or even those in third world countries.
Whitaker takes a thorough look at the actual results of drug
therapies and other treatments on modern-day patients and what he
reveals may stun you. He also gives a hard scrutiny to the politics
behind the psychopharmaeutical industry. This book will remain a
landmark publication on mental health for a very long time.
The book is published by Perseus Publishing.
|
|
Book Review: Children with
Starving Brains: A Medical Treatment Guide for Autism Spectrum Disorder |
| In 1996, Jaquelyn McCandless, M.D.,
discovered that her two-year old granddaughter had been diagnosed with
autism spectrum disorder. "Her diagnosis and unusually compelling
nature," says McCandless, "inspired a reorientation of my professional
life from the practice of psychiatry with a focus on alternative and
anti-aging medicine to an immersion into the biomedical aspects of
autism."
Her recently published book, "Children with Starving Brains: A
Medical Treatment Guide for Autism Spectrum Disorder", is the result of
that immersion. McCandless takes the reader into the latest scientific
research on the many risk factors in autism: toxic reactions, heavy
metal contamination, wheat/milk allergies, viral causes, etc.
This is a much-needed, practical hands-on book for physicians and lay
people alike that gives them real tools in bringing about improvements
and sometimes complete recoveries for those children unfortunate enough
to fall prey to the autism epidemic that has swept the world in recent
decades.
The publisher is Bramble Books. |
|